<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03967132</url>
  </required_header>
  <id_info>
    <org_study_id>AL29A</org_study_id>
    <nct_id>NCT03967132</nct_id>
  </id_info>
  <brief_title>Growth and Tolerance of Infants Fed Milk-Based Infant Formula</brief_title>
  <official_title>Growth and Tolerance of Young Infants Fed Milk-Based Infant Formula With Oligosaccharides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Nutrition</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Nutrition</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate growth and tolerance of healthy term infants fed an
      experimental milk-based infant formula with oligosaccharides compared to a control milk-based
      infant formula.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 8, 2019</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight</measure>
    <time_frame>Day of life 14 - 119</time_frame>
    <description>Weight gain per day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stool Characteristics</measure>
    <time_frame>Study Day 1 to Day of life 119</time_frame>
    <description>Parent completed diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Formula Tolerance</measure>
    <time_frame>Study Day 1 to Day of life 119</time_frame>
    <description>Parent completed diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length</measure>
    <time_frame>Study Day 1 to Day of life 119</time_frame>
    <description>Length gain per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head Circumference (HC)</measure>
    <time_frame>Study Day 1 to Day of life 119</time_frame>
    <description>HC gain per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Illness Incidence</measure>
    <time_frame>Study Day 1 to Day of life 119</time_frame>
    <description>Parent reported incidence of illness</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Stool Sample</measure>
    <time_frame>Study Day 1 to Day of life 119</time_frame>
    <description>Microbiota characterization</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">189</enrollment>
  <condition>Gastro-Intestinal Tolerance</condition>
  <arm_group>
    <arm_group_label>Control Infant Formula</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Milk-based infant formula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Infant Formula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Milk-based Infant Formula with oligosaccharides</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Human-milk fed</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Infant Formula</intervention_name>
    <description>Ready to feed infant formula, feed ad libitum</description>
    <arm_group_label>Control Infant Formula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Experimental Infant Formula</intervention_name>
    <description>Ready to feed infant formula, feed ad libitum</description>
    <arm_group_label>Experimental Infant Formula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Reference Group</intervention_name>
    <description>Human milk, breast feeding ad libitum</description>
    <arm_group_label>Reference Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good health as determined from participant's medical history

          -  Singleton from a full-term birth with a gestational age of 37-42 weeks

          -  Birth weight was &gt; 2490 g (~5 lbs. 8 oz.)

          -  If parent(s) of the participant elect to formula-feed the participant, parent(s)
             confirm the participant has not been given human milk since being discharged from the
             hospital following birth, and confirm their intention to feed their infant the study
             product as the sole source of feeding from Study Visit 1-Visit 7, unless instructed
             otherwise by their healthcare professional.

          -  If parent(s) of the participant elect to feed the infant human milk, they confirm the
             infant has not received any formula prior to enrollment, and confirm their intention
             to exclusively feed human milk from birth, and as the sole source of feeding from
             Study Visit 1-Visit 7.

          -  Parent(s) confirm their intention not to administer vitamin or mineral supplements
             (with the exception of Vitamin D supplements), solid foods or juices to their infant
             from enrollment through the duration of the study, unless instructed otherwise by
             their healthcare professional.

          -  Participant's parent(s) has voluntarily signed and dated an ICF, approved by an
             IRB/IEC and provided HIPAA (or other applicable privacy regulation) authorization
             prior to any participation in the study.

        Exclusion Criteria:

          -  An adverse maternal, fetal or participant medical history that is thought by the
             investigator to have potential for effects on tolerance, growth, and/or development.

          -  Participant is taking and plans to continue taking medications (including over the
             counter (OTC), such as MyliconÂ® for gas), prebiotics, probiotics, home remedies (such
             as juice for constipation), herbal preparations or rehydration fluids that might
             affect GI tolerance.

          -  Participant participates in another study that has not been approved as a concomitant
             study by AN.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timberly Williams, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott Nutrition</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Watching Over Mothers &amp; Babies</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Medical Associates</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwich Pediatric Group, P.C.</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Medical Research LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Research-Deland, LLC a/b/a Accel Clinical Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32829</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Prime</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deaconess Clinic, Inc.</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael W. Simon, M.D., PSC</name>
      <address>
        <city>Nicholasville</city>
        <state>Kentucky</state>
        <zip>40356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Springs Medical Research</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Clinical Research, LLC</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Pediatric Research Center, LLC</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midsouth Center for Clinical Research</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARC Clinical Research at Wilson Parke</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventavia Research Group, LLC</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventavia Research Group</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventavia Research Group, LLC 3078</name>
      <address>
        <city>Keller</city>
        <state>Texas</state>
        <zip>76248</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagan Pediatrics - HD Research Corporation</name>
      <address>
        <city>Pearland</city>
        <state>Texas</state>
        <zip>77584</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plano Pediatrics - ACRC Trials</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 27, 2019</study_first_submitted>
  <study_first_submitted_qc>May 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

